Central European Cooperative Oncology Group

Recent papers from Central European Cooperative Oncology Group

1. Surgery-first versus neoadjuvant chemotherapy in stage I (cT1c) triple-negative breast cancer: A critical reappraisalThe Breast · 2026
2. Diversified legume-based crop rotations enhance nutrient cycling and long-term productivity in tropical no-tillage systemsFrontiers in Environmental Science · 2026
3. Dynamic thymidine kinase activity independently captures treatment-specific biological response and is independently associated with outcomes in endocrine-resistant HR+ /HER2 − metastatic breast cancer: A translational analysis of the GEICAM/2013–02 PEARL trialEuropean Journal of Cancer · 2026
4. Invitations to Publish in a Journal by Email: A Prospective AnalysisLearned Publishing · 2026
5. Diagnosis and treatment of pancreatic cancer: an expert opinion from the 9th CECOG Pancreas Cancer Academymemo - Magazine of European Medical Oncology · 2026
6. Systemic therapy of nonsmall cell lung cancer: breakthroughs during the last five decadesCurrent Opinion in Oncology · 2025
7. Systemic therapy of nonsmall cell lung cancer: breakthroughs during the last five decadesCurrent Opinion in Oncology · 2025
8. Transcriptomic Predictors of Survival for Palbociclib + Endocrine Therapy Versus Capecitabine in Aromatase Inhibitor–Resistant Breast Cancer From the GEICAM/2013-02 PEARL TrialJCO Precision Oncology · 2025
9. Adjuvant therapy in resected non-small cell lung cancer: current status and perspectivesHolistic Integrative Oncology · 2025
10. Phase II trial of HER-Vaxx, a B cell peptide-based vaccine, in HER2-overexpressing advanced gastric cancer patients under platinum-based chemotherapy (HERIZON)Clinical Cancer Research · 2024
11. Breakthrough Infections in SARS-CoV-2-Vaccinated Multiple Myeloma Patients Improve Cross-Protection against Omicron VariantsVaccines · 2024
12. Abstract PO1-04-10: Body Mass Index and Treatment Efficacy in advanced Luminal Breast Cancer: Insights from the GEICAM/2013-02 (PEARL) trialCancer Research · 2024
13. Abstract PO1-15-10: Lower pre-treatment B-cell gene expression signatures correspond with improved overall survival with palbociclib + endocrine therapy in HR+/HER2- metastatic breast cancer: a biomarker analysis from the GEICAM/2013-02 PEARL trialCancer Research · 2024
14. Laying foundations for a “Right to Improve”Frontiers in the Internet of Things · 2024
15. Preclinical and Clinical Observations Implying Combination Therapy to Enhance the Efficacy of the Her-2/neu B-Cell Peptide-Based Vaccine HER-Vaxx and to Prevent Immune EvasionInternational Journal of Molecular Sciences · 2023
16. Preclinical and Clinical Observations Implying Combination Therapy to Enhance the Efficacy of the Her-2/Neu B Cell Peptide-Based Vaccine Her-Vaxx and to Prevent Immune Evasion2023
17. Cetuximab Every 2 Weeks Versus Standard Weekly Dosing Administration ScheduleFuture Oncology · 2023
18. A Framework for Enabling Cloud Services to Leverage Energy Data2023
19. Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer PatientsClinical Cancer Research · 2023
20. CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2− Metastatic Breast CancerClinical Cancer Research · 2023